{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:51:06Z","timestamp":1793393466218,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["090770\/Z\/09\/Z"],"award-info":[{"award-number":["090770\/Z\/09\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["098051"],"award-info":[{"award-number":["098051"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["206194"],"award-info":[{"award-number":["206194"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council UK","doi-asserted-by":"crossref","award":["G0600718"],"award-info":[{"award-number":["G0600718"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000278","name":"Department for International Development","doi-asserted-by":"publisher","award":["MR\/M005212\/1"],"award-info":[{"award-number":["MR\/M005212\/1"]}],"id":[{"id":"10.13039\/501100000278","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1118166"],"award-info":[{"award-number":["OPP1118166"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Long regarded as an epicenter of drug-resistant malaria, Southeast Asia continues to provide new challenges to the control of\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      malaria. Recently, resistance to the artemisinin combination therapy partner drug piperaquine has been observed in multiple locations across Southeast Asia. Genetic studies have identified single nucleotide polymorphisms as well as copy number variations in the\n                      <jats:italic>plasmepsin 2<\/jats:italic>\n                      and\n                      <jats:italic>plasmepsin 3<\/jats:italic>\n                      genes, which encode haemoglobin-degrading proteases that associate with clinical and in vitro piperaquine resistance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      To accurately and quickly determine the presence of copy number variations in the\n                      <jats:italic>plasmepsin 2\/3<\/jats:italic>\n                      genes in field isolates, this study developed a quantitative PCR assay using TaqMan probes. Copy number estimates were validated using a separate SYBR green-based quantitative PCR assay as well as a novel PCR-based breakpoint assay to detect the hybrid gene product. Field samples from 2012 to 2015 across three sites in Cambodia were tested using DNA extracted from dried blood spots and whole blood to monitor the extent of\n                      <jats:italic>plasmepsin 2\/3<\/jats:italic>\n                      gene amplifications, as well as amplifications in the multidrug resistance transporter 1 gene (\n                      <jats:italic>pfmdr1<\/jats:italic>\n                      ), a marker of mefloquine resistance. This study found high concordance across all methods of copy number detection. For samples derived from dried blood spots, a success rate greater than 80% was found in each assay, with more recent samples performing better. Evidence of extensive\n                      <jats:italic>plasmepsin 2\/3<\/jats:italic>\n                      copy number amplifications was observed in Pursat (94%, 2015) (Western Cambodia) and Preah Vihear (87%, 2014) (Northern Cambodia), and lower levels in Ratanakiri (16%, 2014) (Eastern Cambodia). A shift was observed from two copies of\n                      <jats:italic>plasmepsin 2<\/jats:italic>\n                      in Pursat in 2013 to three copies in 2014\u20132015 (25% to 64%).\n                      <jats:italic>Pfmdr1<\/jats:italic>\n                      amplifications were absent in all samples from Preah Vihear and Ratanakiri in 2014 and absent in Pursat in 2015.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The multiplex TaqMan assay is a robust tool for monitoring both\n                      <jats:italic>plasmepsin<\/jats:italic>\n                      2\/3 and\n                      <jats:italic>pfmdr1<\/jats:italic>\n                      copy number variations in field isolates, and the SYBR-green and breakpoint assays are useful for monitoring\n                      <jats:italic>plasmepsin 2\/3<\/jats:italic>\n                      amplifications. This study shows increasing levels of\n                      <jats:italic>plasmepsin 2<\/jats:italic>\n                      copy numbers across Cambodia from 2012 to 2015 and a complete reversion of multicopy\n                      <jats:italic>pfmdr1<\/jats:italic>\n                      parasites to single copy parasites in all study locations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-020-03249-x","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T02:02:57Z","timestamp":1589335377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Development of copy number assays for detection and surveillance of piperaquine resistance associated plasmepsin 2\/3 copy number variation in Plasmodium falciparum"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7131-1610","authenticated-orcid":false,"given":"Megan R.","family":"Ansbro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihir","family":"Kekre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanaki","family":"Amaratunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sokunthea","family":"Sreng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seila","family":"Suon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivo","family":"Miotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick M.","family":"Fairhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Wellems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic P.","family":"Kwiatkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"3249_CR1","volume-title":"World malaria report 2018","author":"WHO","year":"2018","unstructured":"WHO. World malaria report 2018. Geneva: World Health Organization; 2018."},{"key":"3249_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1473-3099(15)00487-9","volume":"16","author":"C Amaratunga","year":"2016","unstructured":"Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin\u2013piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis. 2016;16:357\u201365.","journal-title":"Lancet Infect Dis"},{"key":"3249_CR3","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.1128\/AAC.00366-15","volume":"59","author":"S Chaorattanakawee","year":"2015","unstructured":"Chaorattanakawee S, Saunders DL, Sea D, Chanarat N, Yingyuen K, Sundrakes S, et al. Ex vivo drug susceptibility testing and molecular profiling of clinical Plasmodium falciparum isolates from Cambodia from 2008 to 2013 suggest emerging piperaquine resistance. Antimicrob Agents Chemother. 2015;59:4631\u201343.","journal-title":"Antimicrob Agents Chemother"},{"key":"3249_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S1473-3099(15)70049-6","volume":"15","author":"MD Spring","year":"2015","unstructured":"Spring MD, Lin JT, Manning JE, Vanachayangkul P, Somethy S, Bun R, et al. Dihydroartemisinin\u2013piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015;15:683\u201391.","journal-title":"Lancet Infect Dis"},{"key":"3249_CR5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1128\/AAC.00686-12","volume":"57","author":"R Leang","year":"2013","unstructured":"Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, et al. Efficacy of dihydroartemisinin\u2013piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother. 2013;57:818\u201326.","journal-title":"Antimicrob Agents Chemother"},{"key":"3249_CR6","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1128\/AAC.00835-15","volume":"59","author":"R Leang","year":"2015","unstructured":"Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin\u2013piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719\u201326.","journal-title":"Antimicrob Agents Chemother"},{"key":"3249_CR7","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1056\/NEJMc1403007","volume":"371","author":"DL Saunders","year":"2014","unstructured":"Saunders DL, Vanachayangkul P, Lon C, US Army Military Malaria Research Program, National Center for Parasitology, Entomology and Malaria Control, Royal Cambodian Armed Forces. Dihydroartemisinin\u2013piperaquine failure in Cambodia. N Engl J Med. 2014;371:484\u20135.","journal-title":"N Engl J Med"},{"key":"3249_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S1473-3099(16)30409-1","volume":"17","author":"R Amato","year":"2017","unstructured":"Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, et al. Genetic markers associated with dihydroartemisinin\u2013piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype\u2013phenotype association study. Lancet Infect Dis. 2017;17:164\u201373.","journal-title":"Lancet Infect Dis"},{"key":"3249_CR9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","volume":"17","author":"B Witkowski","year":"2017","unstructured":"Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype\u2013genotype association study. Lancet Infect Dis. 2017;17:174\u201383.","journal-title":"Lancet Infect Dis"},{"key":"3249_CR10","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1038\/s41467-018-05652-0","volume":"9","author":"LS Ross","year":"2018","unstructured":"Ross LS, Dhingra SK, Mok S, Yeo T, Wicht KJ, Kumpornsin K, et al. Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nat Commun. 2018;9:3314.","journal-title":"Nat Commun"},{"key":"3249_CR11","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/infdis\/jix334","volume":"216","author":"S Agrawal","year":"2017","unstructured":"Agrawal S, Moser KA, Morton L, Cummings MP, Parihar A, Dwivedi A, et al. Association of a novel mutation in the Plasmodium falciparum chloroquine resistance transporter with decreased piperaquine sensitivity. J Infect Dis. 2017;216:468\u201376.","journal-title":"J Infect Dis"},{"issue":"9","key":"3249_CR12","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","volume":"19","author":"RW van der Pluijm","year":"2019","unstructured":"van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin\u2013piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis. 2019;19(9):952\u201361.","journal-title":"Lancet Infect Dis"},{"key":"3249_CR13","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S1473-3099(19)30392-5","volume":"19","author":"WL Hamilton","year":"2019","unstructured":"Hamilton WL, Amato R, van der Pluijm RW, Jacob CG, Quang HH, Thuy-Nhien NT, et al. Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. Lancet Infect Dis. 2019;19:952\u201361.","journal-title":"Lancet Infect Dis"},{"key":"3249_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50.","journal-title":"Nature"},{"key":"3249_CR15","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1073\/pnas.022630099","volume":"99","author":"R Banerjee","year":"2002","unstructured":"Banerjee R, Liu J, Beatty W, Pelosof L, Klemba M, Goldberg DE. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc Natl Acad Sci USA. 2002;99:990\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3249_CR16","first-page":"275","volume":"295","author":"DE Goldberg","year":"2005","unstructured":"Goldberg DE. Hemoglobin degradation. Curr Top Microbiol Immunol. 2005;295:275\u201391.","journal-title":"Curr Top Microbiol Immunol"},{"key":"3249_CR17","first-page":"1424","volume":"4","author":"J Wunderlich","year":"2012","unstructured":"Wunderlich J, Rohrbach P, Dalton JP. The malaria digestive vacuole. Front Biosci. 2012;4:1424\u201348.","journal-title":"Front Biosci"},{"key":"3249_CR18","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1128\/AAC.00882-09","volume":"53","author":"PA Moura","year":"2009","unstructured":"Moura PA, Dame JB, Fidock DA. Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother. 2009;53:4968\u201378.","journal-title":"Antimicrob Agents Chemother"},{"key":"3249_CR19","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1128\/AAC.06350-11","volume":"56","author":"MI Veiga","year":"2012","unstructured":"Veiga MI, Ferreira PE, Malmberg M, Jornhagen L, Bjorkman A, Nosten F, et al. pfmdr1 amplification is related to increased Plasmodium falciparum in vitro sensitivity to the bisquinoline piperaquine. Antimicrob Agents Chemother. 2012;56:3615\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"3249_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S1473-3099(19)30689-9","volume":"20","author":"M Silva","year":"2020","unstructured":"Silva M, Calcada C, Teixeira M, Veiga MI, Ferreira PE. Multigenic architecture of piperaquine resistance trait in Plasmodium falciparum. Lancet Infect Dis. 2020;20:26\u20137.","journal-title":"Lancet Infect Dis"},{"key":"3249_CR21","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nm0316-220","volume":"22","author":"A Maxmen","year":"2016","unstructured":"Maxmen A. Back on TRAC: new trial launched in bid to outpace multidrug-resistant malaria. Nat Med. 2016;22:220\u20131.","journal-title":"Nat Med"},{"key":"3249_CR22","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1186\/s12936-019-2955-z","volume":"18","author":"NJ White","year":"2019","unstructured":"White NJ. Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance. Malar J. 2019;18:338.","journal-title":"Malar J"},{"key":"3249_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0140-6736(04)16767-6","volume":"364","author":"RN Price","year":"2004","unstructured":"Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004;364:438\u201347.","journal-title":"Lancet"},{"key":"3249_CR24","doi-asserted-by":"publisher","first-page":"5277","DOI":"10.1128\/AAC.00687-13","volume":"57","author":"P Lim","year":"2013","unstructured":"Lim P, Dek D, Try V, Eastman RT, Chy S, Sreng S, et al. Ex vivo susceptibility of Plasmodium falciparum to antimalarial drugs in western, northern, and eastern Cambodia, 2011\u20132012: association with molecular markers. Antimicrob Agents Chemother. 2013;57:5277\u201383.","journal-title":"Antimicrob Agents Chemother"},{"key":"3249_CR25","doi-asserted-by":"publisher","first-page":"e0005091","DOI":"10.1371\/journal.pntd.0005091","volume":"10","author":"JB Hostetler","year":"2016","unstructured":"Hostetler JB, Lo E, Kanjee U, Amaratunga C, Suon S, Sreng S, et al. Independent origin and global distribution of distinct Plasmodium vivax Duffy binding protein gene duplications. PLoS Negl Trop Dis. 2016;10:e0005091.","journal-title":"PLoS Negl Trop Dis"},{"key":"3249_CR26","doi-asserted-by":"publisher","first-page":"e2489","DOI":"10.1371\/journal.pntd.0002489","volume":"7","author":"D M\u00e9nard","year":"2013","unstructured":"M\u00e9nard D, Chan ER, Benedet C, Ratsimbasoa A, Kim S, Chim P, et al. Whole genome sequencing of field isolates reveals a common duplication of the Duffy binding protein gene in Malagasy Plasmodium vivax strains. PLoS Negl Trop Dis. 2013;7:e2489.","journal-title":"PLoS Negl Trop Dis"},{"key":"3249_CR27","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature01097","volume":"419","author":"MJ Gardner","year":"2002","unstructured":"Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002;419:498\u2013511.","journal-title":"Nature"},{"issue":"Suppl 1","key":"3249_CR28","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.trstmh.2008.11.002","volume":"103","author":"CV Plowe","year":"2009","unstructured":"Plowe CV. The evolution of drug-resistant malaria. Trans R Soc Trop Med Hyg. 2009;103(Suppl 1):S11\u20134.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3249_CR29","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","volume":"359","author":"H Noedl","year":"2008","unstructured":"Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619\u201320.","journal-title":"N Engl J Med"},{"key":"3249_CR30","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"3249_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJM200101253440403","volume":"344","author":"A Djimd\u00e9","year":"2001","unstructured":"Djimd\u00e9 A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001;344:257\u201363.","journal-title":"N Engl J Med"},{"key":"3249_CR32","doi-asserted-by":"publisher","first-page":"565","DOI":"10.4269\/ajtmh.1995.52.565","volume":"52","author":"CV Plowe","year":"1995","unstructured":"Plowe CV, Djimd\u00e9 A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. 1995;52:565\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"3249_CR33","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/0014-4894(92)90209-S","volume":"74","author":"FN Gyang","year":"1992","unstructured":"Gyang FN, Peterson DS, Wellems TE. Plasmodium falciparum: rapid detection of dihydrofolate reductase mutations that confer resistance to cycloguanil and pyrimethamine. Exp Parasitol. 1992;74:470\u20132.","journal-title":"Exp Parasitol"},{"key":"3249_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0166-6851(95)00041-X","volume":"71","author":"P Wang","year":"1995","unstructured":"Wang P, Brooks DR, Sims PF, Hyde JE. A mutation-specific PCR system to detect sequence variation in the dihydropteroate synthetase gene of Plasmodium falciparum. Mol Biochem Parasitol. 1995;71:115\u201325.","journal-title":"Mol Biochem Parasitol"},{"key":"3249_CR35","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/S0035-9203(97)90284-4","volume":"91","author":"B Khan","year":"1997","unstructured":"Khan B, Omar S, Kanyara JN, Warren-Perry M, Nyalwidhe J, Peterson DS, et al. Antifolate drug resistance and point mutations in Plasmodium falciparum in Kenya. Trans R Soc Trop Med Hyg. 1997;91:456\u201360.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3249_CR36","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1086\/514159","volume":"176","author":"CV Plowe","year":"1997","unstructured":"Plowe CV, Cortese JF, Djimd\u00e9 A, Nwanyanwu OC, Watkins WM, Winstanley PA, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine\u2013sulfadoxine use and resistance. J Infect Dis. 1997;176:1590\u20136.","journal-title":"J Infect Dis"},{"key":"3249_CR37","doi-asserted-by":"publisher","first-page":"e1000243","DOI":"10.1371\/journal.pgen.1000243","volume":"4","author":"S Nair","year":"2008","unstructured":"Nair S, Miller B, Barends M, Jaidee A, Patel J, Mayxay M, et al. Adaptive copy number evolution in malaria parasites. PLoS Genet. 2008;4:e1000243.","journal-title":"PLoS Genet"},{"key":"3249_CR38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijpddr.2018.11.004","volume":"9","author":"D Loesbanluechai","year":"2019","unstructured":"Loesbanluechai D, Kotanan N, de Cozar C, Kochakarn T, Ansbro MR, Chotivanich K, et al. Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine. Int J Parasitol Drugs Drug Resist. 2019;9:16\u201322.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"3249_CR39","doi-asserted-by":"publisher","first-page":"e02309","DOI":"10.1128\/AAC.02309-17","volume":"62","author":"A Mukherjee","year":"2018","unstructured":"Mukherjee A, Gagnon D, Wirth DF, Richard D. Inactivation of plasmepsins 2 and 3 sensitizes Plasmodium falciparum to the antimalarial drug piperaquine. Antimicrob Agents Chemother. 2018;62:e02309\u201317.","journal-title":"Antimicrob Agents Chemother"},{"key":"3249_CR40","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.3201\/eid2408.180370","volume":"24","author":"J Inoue","year":"2018","unstructured":"Inoue J, Silva M, Fofana B, Sanogo K, Martensson A, Sagara I, et al. Plasmodium falciparum plasmepsin 2 duplications, West Africa. Emerg Infect Dis. 2018;24:1591\u20133.","journal-title":"Emerg Infect Dis"},{"key":"3249_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3201\/eid2401.170864","volume":"24","author":"H Gupta","year":"2018","unstructured":"Gupta H, Macete E, Bulo H, Salvador C, Warsame M, Carvalho E, et al. Drug-resistant polymorphisms and copy numbers in Plasmodium falciparum, Mozambique, 2015. Emerg Infect Dis. 2018;24:40\u20138.","journal-title":"Emerg Infect Dis"},{"key":"3249_CR42","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12936-019-2756-4","volume":"18","author":"D Leroy","year":"2019","unstructured":"Leroy D, Macintyre F, Adoke Y, Ouoba S, Barry A, Mombo-Ngoma G, et al. African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker. Malar J. 2019;18:126.","journal-title":"Malar J"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03249-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-020-03249-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03249-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T19:22:24Z","timestamp":1620847344000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-020-03249-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3249"],"URL":"https:\/\/doi.org\/10.1186\/s12936-020-03249-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/655209","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]},"assertion":[{"value":"14 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants or guardians provided written consent and samples were collected under approval from the Cambodian National Ethics Committee for Health Research and the National Institute of Allergy and Infectious Diseases Institutional Review board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"181"}}